Danchin Nicolas, Blanchard Didier, Steg Philippe Gabriel, Sauval Patrick, Hanania Guy, Goldstein Patrick, Cambou Jean-Pierre, Guéret Pascal, Vaur Laurent, Boutalbi Youcef, Genès Nathalie, Lablanche Jean-Marc
Service de Cardiologie, Hôpital Européen Georges Pompidou, 20 Rue Leblanc, 75015 Paris, France.
Circulation. 2004 Oct 5;110(14):1909-15. doi: 10.1161/01.CIR.0000143144.82338.36. Epub 2004 Sep 27.
Limited data are available on the impact of prehospital thrombolysis (PHT) in the "real-world" setting.
Of 443 intensive care units in France, 369 (83%) prospectively collected all cases of infarction (< or =48 hours of symptom onset) in November 2000; 1922 patients (median age, 67 years; 73% men) with ST-segment-elevation infarction were included, of whom 180 (9%) received intravenous thrombolysis before hospital admission (PHT). Patients with PHT were younger than those with in-hospital thrombolysis, primary percutaneous interventions, or no reperfusion therapy. Median time from symptom onset to hospital admission was 3.6 hours for PHT, 3.5 hours for in-hospital lysis, 3.2 hours for primary percutaneous interventions, and 12 hours for no reperfusion therapy. In-hospital death was 3.3% for PHT, 8.0% for in-hospital lysis, 6.7% for primary percutaneous interventions, and 12.2% for no reperfusion therapy. One-year survival was 94%, 89%, 89%, and 79%, respectively. In a multivariate analysis of predictors of 1-year survival, PHT was associated with a 0.49 relative risk of death (95% CI, 0.24 to 1.00; P=0.05). When the analysis was limited to patients receiving reperfusion therapy, the relative risk of death for PHT was 0.52 (95% CI, 0.25 to 1.08; P=0.08). In patients with PHT admitted in < or =3.5 hours, in-hospital mortality was 0% and 1-year survival was 99%.
The 1-year outcome of patients treated with PHT compares favorably with that of patients treated with other modes of reperfusion therapy; this favorable trend persists after multivariate adjustment. Patients with PHT admitted very early have a very high 1-year survival rate.
关于院前溶栓(PHT)在“真实世界”环境中的影响,可用数据有限。
在法国的443个重症监护病房中,369个(83%)前瞻性收集了2000年11月所有梗死病例(症状发作≤48小时);纳入了1922例ST段抬高型梗死患者(中位年龄67岁;73%为男性),其中180例(9%)在入院前接受了静脉溶栓(PHT)。接受PHT的患者比接受院内溶栓、直接经皮冠状动脉介入治疗或未接受再灌注治疗的患者更年轻。从症状发作到入院的中位时间,PHT为3.6小时,院内溶栓为3.5小时,直接经皮冠状动脉介入治疗为3.2小时,未接受再灌注治疗为12小时。PHT患者的院内死亡率为3.3%,院内溶栓患者为8.0%,直接经皮冠状动脉介入治疗患者为6.7%,未接受再灌注治疗患者为12.2%。1年生存率分别为94%、89%、89%和79%。在对1年生存率预测因素的多变量分析中,PHT与死亡相对风险0.49相关(95%CI,0.24至1.00;P = 0.05)。当分析仅限于接受再灌注治疗的患者时,PHT的死亡相对风险为0.52(95%CI,0.25至1.08;P = 0.08)。在症状发作≤3.5小时入院的PHT患者中,院内死亡率为0%,1年生存率为99%。
接受PHT治疗的患者1年结局与接受其他再灌注治疗方式的患者相比具有优势;经过多变量调整后,这种有利趋势仍然存在。极早期入院的PHT患者1年生存率非常高。